Drugs & Targets FDA grants priority review for Ziihera in first-line HER2+ GEA May 01, 2026Vol.52 No.17
Cancer Policy One year of reducing animal testing in drug development April 24, 2026Vol.52 No.16By Claire Marie Porter
Cancer Policy FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices April 24, 2026Vol.52 No.16
Drugs & Targets FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer April 24, 2026Vol.52 No.16
Health EquityRegulatory News Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line April 17, 2026Vol.52 No.15By Claire Marie Porter
Cancer Policy FDA adds stereotactic breast biopsy needles to the shortage list April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy FDA issues reminder to sponsors: Disclose clinical trial results April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Drugs & Targets FDA issues draft guidance on genome editing safety standards April 17, 2026Vol.52 No.15
Drugs & Targets FDA clears first HPV self-collection kit and assay for at-home use, marking a step toward improving screening uptake April 10, 2026Vol.52 No.14
